|
Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients
|
05 June 2020 |
|
AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford's potential new vaccine
|
22 May 2020 |
|
AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine
|
30 April 2020 |
|
AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients
|
23 April 2020 |
|
AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19
|
14 April 2020 |
|
AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the fight against COVID-19
|
24 March 2020 |
|
AstraZeneca completes divestment agreement with Atnahs Pharma for established hypertension medicines
|
02 March 2020 |
|
AstraZeneca divests global rights to Movantik
|
25 February 2020 |
|
AstraZeneca divests rights to established hypertension medicines
|
27 January 2020 |
|
Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer
|
20 January 2020 |